RANOLAZINE IN ISCHEMIC HEART DISEASE
https://doi.org/10.20996/1819-6446-2012-8-1-103-109
Abstract
Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.
About the Author
V. P. Lupanov
Institute of Clinical Cardiology named after A.L. Myasnikov , Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
References
1. AСС/АНА 2002 Guidelines Update for the management of patients with chronic stable angina – summary article. A Report of the ACC/AHA Task Force on Practice Guidelines [Committee on management of patients with chronic stable angina]. Circulation 2003; 107: 149-158.
2. Fox K., Garcia M.A., Ardissino D. et al. Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.
3. National guidelines for diagnosis and treatment of stable angina. Kardiovaskulyarnaya Terapiya i Profilaktika 2008; 6 (suppl 4): 1-40. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика 2008; 6 (приложение 4): 1-40).
4. Berger P . Ranolazine and other antianginal therapies in era of the drug-eluting stent. JAMA 2004; 291 (3): 365-367.
5. Bassand J-P . Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14-A19.
6. Aslam S., Gray D. Ranolazine (Renexa) in the treatment of chronic stable angina. Advances in Therapy 2010; 27(4): 193-201.
7. Patel P .D., Arora R.R. Utility of ranolazine in chronic stable angina patients. Cardiovasc Health Risk Manag 2008; 4(4): 819-824.
8. Thadani U., Ezekowitz M., Fenney L., Chiang Y-K; for the Ranolazine Study Group. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placeвo in patients with chronic stable angina pectoris. Circulation 1994; 90: 726-734.
9. Chaitman B.R. Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials. J Cardiovasc Pharmacol Ther 2004; 9(1) suppl: S47-S64.
10. Lee L., Horowitz J., Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-641.
11. Nash D.N., Nash S.D. Ranolazine for chronic stable angina. Lancet 2008; 372: 1335-1341.
12. Vadnais D.S., Wenger N.K. Emerding clinical role of ranolazine in the management of angna. Ther Clin Risk Manag 2010; 6: 517-530.
13. Lopaschuk G.D., Kantor P .F ., Dyck J.R.B. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999;21(2):109-115.
14. Anderson J.R., Nawarskas J.J. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev 2005; 13; 202-210.
15. Pepine C.J., Wolff A.A. A controlled trial a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46-50.
16. Chaitman B.R., Skettino S.L., Parker J.O., et al. for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375-1382.
17. Metelitsa V.I. Handbook of clinical pharmacology of cardiovascular drugs. Moscow: Meditsinskoe In- formatsionnoe Agentstvo; 2005. Russian (Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств, М.: Медицинское информационное агентство; 2005).
18. Rousseau M.F ., Pouleur H., Cocco G., Wolff A.F . Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311-316.
19. Cocco G., Rousseau M.F ., Bouvy T. et al. Effects of a new metabolic modulator , ranolazine, in exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992; 20: 131- 138.
20. Koren M.J., Crager M.R., Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina. The Ranolazine open label experience (ROLE). J Am Coll Cardiol 2007; 49:1027-1034.
21. Cairns J.A. Ranolazine: augmenting the antianginal armamentarium. JACC 2006; 48 (3): 576-578.
22. Conti C.R. Ranolazine and Silent Ischemia. JACC 2011; 58(10): 1083.
23. Stone P .H., Gratsiansky N.A., Blokhin A. et al. for the ERICA investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48: 566-575.
24. Chaitman B.R., Pepine C.J., Parker J.O. et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309-316.
25. Wilson S.R., Scirica B.M., Braunwald E., еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009; 53(17): 1510-1516.
26. Bagger J.P ., Belker H.E., Thomassen A., Nielsen T.T. Effect of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther 1997; 11(3): 479-484.
27. Stone P .H. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4):603-614.
28. Oliver M.F ., Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994; 343: 155-158.
29. Deshmukh S.H, Patel S.R, Pinassi E. et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20(5): 343-347.
30. Тimmis A.D, Chaitman B.R., Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27(1): 42-48.
31. Siddiqui M.A., Keam S.J. Ranolazine: a review of its use in chronic a stable angina pectoris. Drugs 2006; 66 (5): 693-710.
32. Dobesh P .P ., Trujillo T .C. Ranolazine: a new option in the management of chronic stable angina. Pharmacotherapy 2007; 27(12); 1659- 1676.
33. Jerling M., Huan B.L., Leung K. et al. Studies to investigate the pharmacokinetic interaction between ranolazine and ketoconazole, diltiazem or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005; 45: 422-433.
34. Wenger N.K., Chaitman B., Vetrovec G.W. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol 2007; 99: 11-18.
35. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110; 904-910.
36. Keating G.M. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 2008; 68(17): 2483-2503.
37. Reddy B.M.,Weintraub H.S., Schwartzbard A.Z. Ranolazine. A New Approach to Treating an Old Problem. Tex Heart Inst J 2010; 37(6): 641- 647.
38. Michels G., Kochanek M., Hoppe U.C. Ranolazine — an additional anti-anginal drug. Dtsch Med Wochenschr 2010 135(41):2037-2040.
39. Maier L.S. A novel mechanism for treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 2009; 54(4): 279-286.
40. Truffa A.M., Newby L.K., Melloni. C. Extended-release ranolazine: critical evaluation of its use in stable angina. Vasc Health Risk Manag 2011; 7: 536-539.
41. Stone P .Y . The Anti-Ischemic Mechanism of Action of Ranolazine in Stable Ischemic Heart Disease. JACC 2010; 56(12): 934-942.
42. Makielski J.С, Valdivia C.R. Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more? Br J Pharmacol 2006; 148(1): 4-6.
43. Reffelmann T., Kloner R.A. Ranolazine: anti-anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8(3): 319-329.
Review
For citations:
Lupanov V.P. RANOLAZINE IN ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2012;8(1):103-109. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-1-103-109
Views: 1295
Email this article 